Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening disorder of unknown aetiology and pathophysiology. Because of its low incidence, geographical variations and heterogeneous presentation, PPCM continues to be incompletely characterized and understood.
Diagnosis of PPCM is based on four primary criteria, as outlined by the workshop recommendations of the National Heart Lung and Blood Institute and the Office of Rare Diseases (Pearson et al. 2000), as follows:
It is essential to remove the possibility of it being another cardiocascular disease. At present PPCM is considered a form of dilated cardiomyopathy and is treated according the guidelines for dilated cardiomyopathy with no specific therapy (Sliwa et al. 2006a). Treatment includes pharmacotherapy for heart failure with ACE-inhibitors, beta-blockers, vasodilators and diuretics. (standard therapy for heart failure) (Sliwa et al. 2006a).
Peripartum Cardiomyopathy with left ventricular thrombus. K. Sliwa, Soweto Cardiovascular Research Unit.
Nevertheless the prognosis of affected women is poor with deterioration reported in up to 50% of cases despite optimal medical treatment and a mortality rate as high as 15%. Only 23% of patients are said to recover fully. (Brar et al. 2007, Elkayam et al. 2005, Reimold et al. 2001, Sliwa et al. 2000, 2002, 2006a).
© 2017 European Society of Cardiology. All rights reserved